Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.83 |
| ▸ | SLC5A1 | P13866 | 12/20 | 0.83 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.75 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12750452 | 1.00 | SLC5A2 (0.83) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12167414 | 1.00 | SLC5A2 (0.83) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17034642 | 0.91 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL207789 | 0.91 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12781952 | 0.91 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13626079 | 0.91 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL29837082 | 0.91 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12513682 | 0.91 | SLC5A2 (0.84) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL254518 | 0.89 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL500069 | 0.89 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127343-A1 | NOVEL COMPOUNDS FOR TREATING DIABETES | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2018-05-10 | — | — | US | disclosed |
| US-20170196985-A1 | SULFUR(VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2017-07-13 | — | — | US | disclosed |
| US-9550747-B2 | Dapagliflozin crystalline form and preparation method thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-01-24 | — | — | US | disclosed |
| US-20160347731-A1 | DAPAGLIFLOZIN CRYSTALLINE FORM AND PREPARATION METHOD THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD (CN) | 2016-12-01 | — | — | US | disclosed |
| US-9453039-B2 | Crystal structures of SGLT2 inhibitors and processes for preparing same | ASTRAZENECA AB (SE) | 2016-09-27 | — | — | US | disclosed |
| US-8883743-B2 | Methods for treating obesity employing an SGLT2 inhibitor | ASTRAZENECA AB (SE) | 2014-11-11 | — | — | US | disclosed |
| US-20130303467-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | ASTRAZENECA AB (SE) | 2013-11-14 | — | — | US | disclosed |
| US-8501698-B2 | Crystal structures of SGLT2 inhibitors and processes for preparing same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| US-8450286-B2 | Method for treating cancers having high glucose requirements employing an SGLT2 inhibitor and compositions thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-28 | — | — | US | disclosed |
| US-8361972-B2 | Pharmaceutical formulations containing an SGLT2 inhibitor | BRISTOL MYERS-SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110065658-A1 | METHOD FOR TREATING HYPERURICEMIA EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITION CONTAINING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110015141-A1 | METHOD FOR TREATING CANCERS HAVING HIGH GLUCOSE REQUIREMENTS EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITIONS THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-20 | — | — | US | disclosed |
| US-20100167988-A1 | ETHOXYPHENYLMETHYL INHIBITORS OF SGLT2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100081625-A1 | METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| US-7687469-B2 | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-30 | — | — | US | disclosed |
| US-7589193-B2 | C-aryl glucoside SGLT2 inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080287529-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-20 | — | — | US | disclosed |
| US-20080234367-A1 | Sodium dependent glucose transporter (SGLT2); such as dapagliflozin, dapagliflozin-PGS, a C-glucoside or an O-glucoside | BRISTOL-MYERS SQUIBB (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1828216-B1 | GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INT (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-20080004336-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287529-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | SLC5A2, SLC5A1, SLC2A1 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1681/4885 |
| US-20170196985-A1 | SULFUR(VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF | CYP2F1, NAF1, CYP2S1 | SLC5A2 1851/4885SLC5A1 1118/4885ADRA2A 1681/4885 |
| US-20100081625-A1 | METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS | HTT, SNCA, PSEN2 | SLC5A2 59/4885SLC5A1 41/4885ADRA2A 2392/4885 |
| US-20110015141-A1 | METHOD FOR TREATING CANCERS HAVING HIGH GLUCOSE REQUIREMENTS EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITIONS THEREOF | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 2753/4885 |
| US-20100167988-A1 | ETHOXYPHENYLMETHYL INHIBITORS OF SGLT2 | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 550/4885 |
| US-20130303467-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | SLC5A2, SLC5A1, GLP1R | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 255/4885 |
| US-20180127343-A1 | NOVEL COMPOUNDS FOR TREATING DIABETES | GPR119, SLC5A2, DPP4 | SLC5A2 2/4885SLC5A1 5/4885ADRA2A 2019/4885 |
| US-20110065658-A1 | METHOD FOR TREATING HYPERURICEMIA EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITION CONTAINING SAME | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1450/4885 |
| US-20160347731-A1 | DAPAGLIFLOZIN CRYSTALLINE FORM AND PREPARATION METHOD THEREOF | SLC5A2, SLC5A1, SLC2A8 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1448/4885 |
| US-20080234367-A1 | Sodium dependent glucose transporter (SGLT2); such as dapagliflozin, dapagliflozin-PGS, a C-glucoside or an O-glucoside | SLC5A2, SLC5A1, SLC2A1 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1064/4885 |
| US-20080004336-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | SLC5A2, SLC5A1, GLP1R | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.